VIRTUAL DISEASE MODELS

Computational mapping of the compendium of interactions between human physiological systems and disease at a protein-molecule level.

NOVEL DRUG TARGETS

Identifying and validating novel molecules to target against disease based on our in silico models. 

IN SILICO SIMULATIONS

Simulation and predictive analyses of potential outcomes derived from targeted clinical interventions

OUR STORY

Our technology offers a tool for pre-screening molecules prior to initiating actual costly, time consuming and risky clinical trials. By use of our technology, the research organisation will be able to test hypotheses prior to incurring these costs and risks. A wide array of candidate chemical pathways and drug targets will be narrowed by the user prior to first administration of experimental drug in patients.

OUR VISION

In addition to the benefits of being able to model oncological and nervous system disease as well as interventions in a non-animal model, our simulation engine lays the groundwork for potential use across a large number of clinical settings related to the immune system

OUR TECHNOLOGY

Our platform features a robust annotation from which the simulation engine is established. Simulations of physiological events and probable endpoints are further supported by real world evidence from existing clinical trials. The Simmunome is also structured to integrate new emerging data to ensure we stay at the forefront of cutting edge research.